CDK4/6 Inhibitors for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer 04/13/21
Treatment for metastatic breast cancer has undergone major changes in recent years. This includes the addition of a new class of drugs that combats resistance to endocrine therapy resistance: the CKD4/6 inhibitors (CDK4/6i), palbociclib, ribociclib, and abemaciclib. CDK4/6 inhibitors, when added to endocrine therapy in the 1st- and 2nd-line setting, improve progression-free and overall survival in women with hormone-receptor positive, HER2 negative, metastatic breast cancer. Use of CDK4/6 inhibitors requires careful monitoring. The goals of this continuing education program are to increase knowledge about benefits of CDK4/6i in women with metastatic breast cancer and to increase competency in monitoring and managing key side effects of these new drugs. Each 1 hr session will include a didactic component presented by Dr. Linda Sutton, Dr. Gretchen Kimmick or Dr. Melanie Thomas followed by a focus group discussion led by Rebecca Shelby, PhD. Participants will be invited from Duke Cancer Network sites. Each of the sessions will include 6-10 participants to include physicians, advanced practice providers, nurses, clinic administration, pharmacists, pharmacy techs and other site staff who could benefit from the education. (participants only attend one session.) The program will be offered: 3/16/21, 3/23/21, 3/26/21, 4/6/21, 4/13/21 and 4/27/21.
Reviewed evidence supporting use of CDK4/6 Inhibitors (CDK4/6i) in treatment of hormone receptor positive, HER2 negative, metastatic breast cancer.
- 1.00 ACPE - Pharmacist
- 1.00 ACPE - Pharmacy Technician
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ANCC
- 1.00 Attendance
- 1.00 JA Credit - AH
- 1.00 Approved for AMA PRA Category 1 Credit(s)™